BCCs in Gorlin Syndrome Patients
1 clinical trials · Condition
◉ Watch BCCs in Gorlin Syndrome Patients
| Record | Firm | Date |
|---|---|---|
| CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome (NCT04893486) | Palvella Therapeutics, Inc. | 2021-05-06 |
Track BCCs in Gorlin Syndrome Patients automatically
Every clearance here is in the API, with alerts when new ones post.